[1]向利珠罗述善李云波黄海涛** 黄文玲卜晓玲耿韦华.基于医院数据和网络药理学的中药治疗子宫腺肌病用药规律分析[J].现代中医药,2024,(05):104-115.[doi:10.13424/j.cnki.mtcm.2024.05.019]
　XIANG Lizhu LUO Shushan LI YunboHUANG HaitaoHUANG Wenling BU Xiaoling GENG Weihua.Analysis of Medication Patterns for Traditional ChineseMedicine Treatment of Adenomyosis Based onHospital Data and Network Pharmacology[J].Modern Traditional Chinese Medicine,2024,(05):104-115.[doi:10.13424/j.cnki.mtcm.2024.05.019]
点击复制

基于医院数据和网络药理学的中药治疗子宫腺肌病用药规律分析()
分享到：

《现代中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2024年05期
页码:
104-115
栏目:
出版日期:
2024-09-20

文章信息/Info

Title:
Analysis of Medication Patterns for Traditional ChineseMedicine Treatment of Adenomyosis Based onHospital Data and Network Pharmacology
文章编号:
1672-0571(2024)04-0100-09
作者:
向利珠1罗述善2李云波1黄海涛3** 黄文玲3卜晓玲3耿韦华3
1.北京中医药大学第三附属医院，北京 100029；
2.河北大学，保定 071002；
3.北京中医药大学东方医院，北京 100078
Author(s):
XIANG Lizhu1 LUO Shushan2 LI Yunbo1HUANG Haitao3HUANG Wenling3 BU Xiaoling3 GENG Weihua3
1.Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine，Beijing 100029，China；
2.Hebei University，Hebei Baoding 071002，China；
3.Dongfang Hospital of Beijing University of Traditional Chinese Medicine，Beijing 100078，China
关键词:
关键词：子宫腺肌病; 痛经; 数据挖掘; 辨治规律; 网络药理学; 作用机制; 延胡索; 赤芍
Keywords:
Key words:Adenomyosis; Dysmenorrhea; Data mining; Differentiation and treatment rules; Network pharmacology; Mechanism of action; Yanhusuo; Chishao
分类号:
R271.9
DOI:
10.13424/j.cnki.mtcm.2024.05.019
文献标志码:
A
摘要:
摘 要：目的 通过数据挖掘和网络药理学分析子宫腺肌病（adenomyosis，AM）的用药规律及作用机制。方法 收集2017年1月—2020年12月在北京中医药大学附属东方医院诊断为AM患者的中药信息，构建中医药治疗AM的数据库，运用中医传承辅助平台软件(V2.5)进行用药规律分析，运用TCMSP检索高频药对化合物及治疗靶点，与Genecards、DisGeNET、DrugBank和OMIM数据库筛选出AM的靶点相映射并取交集，STRING数据平台构建可视化蛋白-蛋白相互作用（Protein-protein interactions，PPI）网络模型，利用Metascape对关键靶点进行GO和KEGG富集分析。结果 共收集处方1293条，其中涉及使用的中药293味，总频数21136次。性味归经中以寒、温，苦、甘、辛，“肝”、“脾”为主。关联规则54条，新方分析7个。高频药对延胡索-赤芍缓解AM痛经情况的关键靶点59个，KEGG通路157条。关键靶点为TNF、AKT1、TP53、VEGFA、IL-6、HIF-1A、MMP9、MMP2、IL-1β等，主要通路为癌症信号通路、PI3K-Akt、HIF-1、IL-17信号通路。结论 活血化瘀止痛，软坚散结消癥的药物为治疗AM的主要药物，且核心药物延胡索-赤芍治疗AM痛经症状的潜在信号通路可为中药的疗效机制研究提供思路。
Abstract:
Abstract：Objective To analyze the medication pattern and mechanism of action of adenomyosis (AM) through data mining and network pharmacology.Methods Collect traditional Chinese medicine information of patients diagnosed with AM at Dongfang Hospital Affiliated to Beijing University of Traditional Chinese Medicine from January 2017 to December 2020，construct a database for the treatment of AM with traditional Chinese medicine，use the Traditional Chinese Medicine Inheritance Assistance Platform software (V2.5) to analyze medication patterns，use TCMSP to search for high-frequency drug pairs and treatment targets，and map them to Genecards，DisGeNET，DrugBank，and OMIM databases to screen AM targets and take intersections.The STRING data platform constructs a visual protein-protein interactions (PPI) network model，and uses Metascape to perform GO and KEGG enrichment analysis on key targets.Results A total of 1293 prescriptions were collected，including 293 traditional Chinese medicines used，with a total frequency of 21136 times.The nature and taste is mainly characterized by coldness，warmth，bitterness，sweetness，and spiciness in the meridians，with “liver” and “spleen” as the main components.There are 54 association rules and 7 new analysis rules.There are 59 key targets and 157 KEGG pathways for high-frequency drugs to alleviate AM dysmenorrhea with Corydalis yanhusuo and Paeonia lactiflora.The key targets are TNF，AKT1，TP53，VEGFA，IL-6，HIF-1A，MMP9，MMP2，IL-1β，etc.The main pathways are the cancer signaling pathway，PI3K Akt，HIF-1，IL-17 signaling pathway.Conclusion The main drugs for treating AM are those that promote blood circulation，remove blood stasis，relieve pain，and soften hardness，disperse nodules，and eliminate symptoms.The potential signaling pathway of the core drug Yanhusuo Chishao in treating AM dysmenorrhea symptoms can provide ideas for the study of the therapeutic mechanism of traditional Chinese medicine.

参考文献/References:

［1］ZHAI JY，VANNUCCINI S，PETRAGLIA F，et al.Adenomyosis:mechanisms and pathogenesis［J］.Seminars in Reproductive Medicine，2020，38(2/03):129-143.
［2］GRAZIANO A，MONTE GL，PIVA I，et al.Diagnostic findings in adenomyosis:a pictorial review on the major concerns［J］.European Review for Medical and Pharmacological Sciences，2015，19(7):1146-1154.
［3］PINZAUTI S，LAZZERI L，TOSTI C，et al.Transvaginal sonographic features of diffuseadenomyosis in 18-30-year-old nulligravid women without endometriosis：association with symptoms［J］.Ultrasound in Obstetrics and Gynecology，2015，46(6):730-736.
［4］SZUBERT M，KOZIROG E，WILCZYNSKI J.Adenomyosis as a risk factor for myometrial or endometrial neoplasms—review［J］.International Journal of Environmental Research and Public Health，2022，19(4):2294.
［5］郭孙伟，刘惜时.子宫腺肌病发病机制和病理生理研究进展［J］.山东大学学报(医学版)，2022，60(7):6-19.
［6］VANNUCCINI S，LUISI S，TOSTI C，et al.Role of medical therapy in the management of uterine adenomyosis［J］.Fertility and Sterility，2018，109(3):398-405.［LinkOut］
［7］国家药典委员会.中华人民共和国药典［S］.一部.北京:中国医药科技出版社，2020.
［8］RU JL，LI P，WANG JN，et al.TCMSP:a database of systems pharmacology for drug discovery from herbal medicines［J］.Journal of Cheminformatics，2014，6:13.
［9］LI JS，ZHAO P，LI Y，et al.Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease［J］.Scientific Reports，2015，5:15290.
［10］SOUDY M，ANWAR AM，ALI AHMED E，et al.UniprotR:Retrieving and visualizing protein sequence and functional information from Universal Protein Resource (UniProt knowledgebase)［J］.Journal of Proteomics，2020，213:103613.
［11］OTASEK D，MORRIS JH，BOUAS J，et al.Cytoscape Automation:empowering workflow-based network analysis［J］.Genome Biology，2019，20(1):185.
［12］SAFRAN M，DALAH I，ALEXANDER J，et al.GeneCards Version 3:the human gene integrator［J］.Database，2010，2010:baq020.
［13］PIERO J，BRAVO ，Queralt-Rosinach N，et al.DisGeNET:a comprehensive platform integrating information on human disease-associated genes and variants［J］.Nucleic Acids Research，2017，45(D1):D833-D839.
［14］WISHART DS，FEUNANG YD，GUO AC，et al.DrugBank 5.0:a major update to the DrugBank database for 2018［J］.Nucleic Acids Research，2018，46(D1):D1074-D1082.
［15］AMBERGER JS，HAMOSH A.Searching online Mendelian inheritance in man (OMIM):a knowledgebase of human genes and genetic phenotypes［J］.Current Protocols in Bioinformatics，2017，58:1.2.1-1.2.1.2.12.
［16］SZKLARCZYK D，GABLE AL，LYON D，et al.STRING v11:protein-protein association networks with increased coverage，supporting functional discovery in genome-wide experimental datasets［J］.Nucleic Acids Research，2019，47(D1):D607-D613.
［17］杨舫，赵红.子宫腺肌病的中医研究及进展［J］.中日友好医院学报，2018，32(2):98-101.
［18］王领弟，李盼盼，张芳，等.基于中医传承辅助平台的中医药治疗子宫腺肌病用药规律分析及研究［J］.时珍国医国药，2018，29(3):742-744.
［19］黄元御.玉楸药解［M］.北京:中国医药科技出版社，2017:12.
［20］HE K，GAO JL，ZHAO GS.Advances in studies on chemistry，pharmacology，and quality control of Corydalis yanhusuo［J］.Chinese Traditional and Herbal Drugs，2007，38(12):1909-1911.
［21］王红，田明，王淼，等.延胡索现代药理及临床研究进展［J］.中医药学报，2010，38(6):108-111.
［22］杨鑫宝，杨秀伟，刘建勋.延胡索物质基础研究［J］.中国中药杂志，2014，39(1):20-27.
［23］YANG XB，LIU YZ，YANG XW，et al.Study on chemical constituents from Corydalis Rhizoma in Pan’an［J］.Chinese Traditional and Herbal Drugs，2013，44(16):2200-2207.
［24］吴玲芳，王子墨，赫柯芊，等.赤芍的化学成分和药理作用研究概况［J］.中国实验方剂学杂志，2021，27(18):198-206.
［25］董国菊.赤芍总苷药理作用的研究进展［J］.环球中医药，2017，10(9):1157-1160.
［26］何泽源，张妍妍，林楠，等.赤芍化学成分和药理作用及质量标志物的预测分析［J］.中药材，2020，43(12):3074-3079.
［27］张石凯，曹永兵.赤芍的药理作用研究进展［J］.药学实践杂志，2021，39(2):97-101.
［28］世界中医学会联合会.网络药理学评价方法指南［J］.世界中医药，2021，16(4):527-532.
［29］BENAGIANO G，BROSENS I，HABIBA M.Structural and molecular features of the endomyometrium in endometriosis and adenomyosis［J］.Human Reproduction Update，2014，20(3):386-402.
［30］IDRISS HT，NAISMITH JH.TNF alpha and the TNF receptor superfamily:structure-function relationship(s)［J］.Microscopy Research and Technique，2000，50(3):184-195.
［31］SOTNIKOVA N，ANTSIFEROVA I，MALYSHKINA A.Cytokine network of eutopic and ectopic endometrium in women with adenomyosis［J］.American Journal of Reproductive Immunology，2002，47(4):251-255.
［32］ZHIHONG N，YUN F，PINGGUI Z，et al.Cytokine profiling in the eutopic endometrium of adenomyosis during the implantation window after ovarian stimulation［J］.Reproductive Sciences，2016，23(1):124-133.
［33］张凤舜.IL-6、TNF-ɑ在子宫内膜异位症和子宫腺肌病发生发展中作用的研究［D］.长春:吉林大学，2022.
［34］王小霞，康佳丽，邵雪飞，等.GnRHa对子宫腺肌病在位内膜细胞凋亡及VEGF分泌的影响［J］.细胞与分子免疫学杂志，2012，28(1):72-75.
［35］刘姝，张辉，赵兴波，等.子宫腺肌病中PTEN和Akt的表达及其相关性研究［J］.山东大学学报(医学版)，2009，47(10):86-90.
［36］廖姿，张家琼，付先芸，等.基于网络药理学的“大黄-桃仁”配伍治疗子宫腺肌病的作用机制研究［J］.中国中药杂志，2020，45(17):4112-4119.
［37］CARRARELLI P，YEN CF，FUNGHI L，et al.Expression of inflammatory and neurogenic mediators in adenomyosis［J］.Reproductive Sciences，2017，24(3):369-375.
［38］XIANG YQ，SUN YB，YANG BX，et al.Transcriptome sequencing of adenomyosis eutopic endometrium:a new insight into its pathophysiology［J］.Journal of Cellular and Molecular Medicine，2019，23(12):8381-8391.
［39］KANG S，ZHAO JA，LIU Q，et al.Vascular endothelial growth factor gene polymorphisms are associated with the risk of developing adenomyosis［J］.Environmental and Molecular Mutagenesis，2009，50(5):361-366.
［40］HARMSEN MJ，ARDU A，BLEEKER MCG，et al.Increased angiogenesis and lymphangiogenesis in adenomyosis visualized by multiplex immunohistochemistry［J］.International Journal of Molecular Sciences，2022，23(15):8434.
［41］HUANG TS，CHEN YJ，CHOU TY，et al.Oestrogen-induced angiogenesis promotes adenomyosis by activating the Slug-VEGF axis in endometrial epithelial cells［J］.Journal of Cellular and Molecular Medicine，2014，18(7):1358-1371.
［42］薛源，林雪艳，徐歌，等.低氧诱导因子-1α在子宫内膜异位症患者血清中的表达和对在位子宫内膜间质细胞上皮-间质转化的影响［J］.山东大学学报(医学版)，2021，59(2):41-47.

相似文献/References:

[1]符雅惠 朱振宁.自拟痛经贴联合艾灸治疗 １１４例寒凝血瘀型痛经的临床研究[J].现代中医药,2018,(06):014.[doi:10.13424/j.cnki.mtcm.2018.06.006]
[2]付宏伟 耿连岐 宗振勇 刘西贤 张静莎.“恶血归肝”理论及其在痛经中的应用[J].现代中医药,2021,(03):060.[doi:10.13424/j.cnki.mtcm.2021.03.012]
　FUHongwei,GENGLianqi,ZONGZhenyong,et al.Theoryof“EvilbloodReturnstoLiver”andItsApplicationinDysmenorrhea[J].Modern Traditional Chinese Medicine,2021,(05):060.[doi:10.13424/j.cnki.mtcm.2021.03.012]

备注/Memo

备注/Memo:
基金项目：国家青年自然科学基金项目（81704112）
更新日期/Last Update: 2024-09-20